Key facts
- It has raised $570K; the latest was Angel (individual) ($290K) in Feb 2026.
- Notable investors include Lazio Innova, CDP Venture Capital (Rome), Berkeley SkyDeck, AC75 Startup Accelerator, Almacube.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for GeneSys Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for GeneSys Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GeneSys Bio
Developer of advanced diagnostic technology designed for rapid and accurate detection of pathogens in various environments. The company's platform offers quick, sensitive, and portable testing capabilities, enabling healthcare professionals to diagnose infectious diseases and antibiotic resistance efficiently, enhancing patient care and monitoring capabilities.
- Sector
- Healthcare
- HQ
- Montefiascone, Italy
- Employees
- 3
- Website
- genesysbio.com/
- Ownership
- Privately Held (backing)
GeneSys Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GeneSys Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GeneSys Bio in its N-PORT filings yet. We sweep new filings monthly.